Next Generation Tumor Targets
Targeting novel tumor antigens for greater specificity and multifunctional anti-tumor activity.
A New Chapter
Synergy Immunotherapeutics (IMT), is dedicated to developing high-efficacy cancer treatments for patients in need. Our work is focused on promising proprietary solid tumor antigens and multispecific therapeutics. Targeting these specific markers inhibits tumor growth in both in vitro and in animal cancer models. Their unique biological properties together with our multispecific therapeutic approach enable strategies to overcome critical clinical challenges, such as drug resistance, tumor heterogeneity, metastasis, and the immunosuppressive tumor microenvironment.
Emerging Therapeutic Solutions
Novel tumor antigens have been effectively targeted with monospecific antibodies, antibody drug conjugates (ADCs), T cell engagers (TCE) and with innovative multispecific recombinant antibodies and proteins. Given the properties of the tumor antigens, there is high potential for a novel adjuvant or stand-alone therapeutic and for synergy with certain approved cancer therapeutics to kill tumor cells and induce or revitalize an anti-tumor immune response. AI is integrated to accelerate and enhance development from discovery to investigative new drug.
